bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic

bioAffinity announced that it received a Hong Kong patent protecting the proprietary technology underlying its noninvasive CyPath Lung diagnostic for lung cancer. The patent strengthens intellectual-property protection in Hong Kong for the company’s diagnostic platform, but the release provides no revenue, clinical-validation, or commercialization metrics.